Recipient organisationNIHR Oxford Biomedical Research Centre
NIHR supportRecorded as supported by this research centre
PeriodFeb 2025 — Apr 2039
In plain English
AI plain-English summary
Every six months, people with cirrhosis undergo an ultrasound scan to catch liver cancer early, but ultrasound often misses early tumours. This matters because cirrhosis—caused by alcohol, fatty liver, or hepatitis—raises cancer risk, yet the standard surveillance tool is unreliable. Some patients, such as those with advanced cirrhosis or hepatitis B, face especially high risk and need better detection. Current alternatives like CT or contrast MRI are too expensive, toxic, or impractical for repeated use. MRI without contrast is cheaper, non-toxic, and takes only 20 minutes, and early experience suggests it spots cancers that ultrasound misses. If this research succeeds, it could replace ultrasound surveillance with a quick, safe MRI for high-risk patients. That would mean catching more liver cancers at a curable stage, reducing deaths without added radiation or cost burdens on the NHS. The study is a feasibility trial—it will test whether this abbreviated MRI can work as a routine surveillance tool, comparing it head-to-head with ultrasound in people at highest risk. If feasible, it could reshape how liver cancer screening is delivered, quietly improving survival for thousands of patients each year.
View original technical description
People with any condition that affects the liver over a long period of time can develop cirrhosis. Conditions that can lead to cirrhosis include alcohol excess, liver steatosis (lipid or fat accumulation in the liver) and infection with hepatitis B and C. One concern about people with cirrhosis is that they are at increased risk of developing liver cancer. People with cirrhosis are recommended to have an ultrasound scan (USS) every 6 months (surveillance) so that if a cancer develops, it is diagnosed at an early stage when it can be cured. However, ultrasound can miss early cancers even in people having scans every 6 months. Furthermore, the risk of cancer is not uniform among people with cirrhosis. For example, people with more advanced cirrhosis and those with cirrhosis from hepatitis B are at higher risk. It is therefore possible that better tests than ultrasound are needed for people with cirrhosis who are at particularly high risk of cancer. Computed tomography (CT) and Magnetic Resonance Imaging (MRI) scans with dye injection (contrast) are used for liver cancer diagnosis. However, they cannot be done every 6 months because of costs, capacity and toxicity from high CT radiation doses, and MRI contrast accumulation in the brain with repeated MRI contrast injections. MRI scans without contrast are not toxic, cheaper and could be done in 20 minutes, so could be done every 6 months. In our experience, MRI without contrast may raise suspicion of liver cancer in cases missed by ultrasound, so it could be used for surveillance instead. In this study we want to find out if it is feasible to use a quick MRI without contrast as surveillance for hepatocellular cancer (HCC) in people at high risk of liver cancer due to cirrhosis and to compare this MRI with ultrasound.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know